troglitazone has been researched along with Cancer of the Urinary Tract in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshimura, R | 1 |
| Matsuyama, M | 1 |
| Hase, T | 1 |
| Tsuchida, K | 1 |
| Kuratsukuri, K | 1 |
| Kawahito, Y | 1 |
| Sano, H | 1 |
| Segawa, Y | 1 |
| Nakatani, T | 1 |
1 other study available for troglitazone and Cancer of the Urinary Tract
| Article | Year |
|---|---|
The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Humans; Immunologic Factors; Ligands; Pro | 2003 |